Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

Abstract

Primary liver cancers constitute the fourth most deadly group of cancers. Their poor prognosis is due in part to the pre-existence and/or development, often during treatment, of powerful mechanisms accounting for the poor response of cancer cells to antitumor drugs. These include both impaired gene expression and the appearance of spliced variants, polymorphisms and mutations, affecting the function of genes leading to the reduction in intracellular concentrations of active agents, changes in molecular targets and survival pathways, altered tumor microenvironment and phenotypic transition. The present review summarizes available information regarding the role of germline and somatic mutations affecting drug transporters, enzymes involved in drug metabolism, organelles and signaling molecules related to liver cancer chemoresistance. A more complete picture of the actual complexity of this problem is urgently needed for carrying out further pharmacogenomic studies aimed to improve the management of patients suffering from hepatocellular carcinoma or cholangiocarcinoma.

Keywords

Anticancer drug / chemoresistance / chemotherapy / cholangiocarcinoma / germline mutation / hepatoma / liver cancer / somatic mutation

References

[1] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[2] Llovet JM.Molecular targeted therapies in hepatocellular carcinoma..Hepatology2008;48:1312-27 PMCID:PMC2597642

[3] Yao S,Hu Q,Liu B.Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations..Oncotarget2016;7:40491-9 PMCID:PMC5130022

[4] Witt-Kehati D,Alaluf MB,Shlomai A.Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma cells with hepatitis b virus..Transl Oncol2018;11:511-7 PMCID:PMC5884218

[5] EASLEASL clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[6] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[7] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[8] Jindal A,Shailubhai K.Hepatocellular carcinoma: etiology and current and future drugs..J Clin Exp Hepatol2019;9:221-32 PMCID:PMC6477125

[9] Macias RIR,Rodrigues PM,Castro RE.Diagnostic and prognostic biomarkers in cholangiocarcinoma..Liver Int.2019;39 Suppl 1:108-22

[10] Banales JM,Arbelaiz A,Muntane J.Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis..Hepatology2018;

[11] Banales JM,Carpino G,Andersen JB.Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the european network for the study of cholangiocarcinoma (ENS-CCA)..Nat Rev Gastroenterol Hepatol2016;13:261-80

[12] Marin JJG,Herraez E,Di Giacomo S.Chemoresistance and chemosensitization in cholangiocarcinoma..Biochim Biophys Acta Mol Basis Dis2018;1864:1444-53

[13] den Dunnen JT,Maglott DR,Greenblatt MS.HGVS recommendations for the description of sequence variants: 2016 Update..Hum Mutat2016;37:564-9

[14] Sprowl JA.Uptake carriers and oncology drug safety..Drug Metab Dispos2014;42:611-22 PMCID:PMC3965905

[15] Zimmerman EI,Roberts JL,Orwick SJ.Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide..Clin Cancer Res2013;19:1458-66 PMCID:PMC3602278

[16] Gong IY.Impact of genetic variation in OATP transporters to drug disposition and response..Drug Metab Pharmacokinet2013;28:4-18

[17] Bins S,El Bouazzaoui S,Oomen-de Hoop E.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity..Pharmacogenomics2016;17:1483-90

[18] Levi F,Saffroy R,Boige V.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)..Br J Cancer2017;117:965-73 PMCID:PMC5625679

[19] Sakata T,Kimura T,Fukutomi T.Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms..J Pharmacol Sci2010;113:263-6

[20] Chen L,Schlessinger A,Stryke D.Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin..Pharmacogenet Genomics2010;20:687-99 PMCID:PMC2976715

[21] Wong AL,Yeo WL,Ng SS.Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients..Cancer Genomics Proteomics2011;8:255-9

[22] Soo RA,Ng SS,Yong WP.Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients..Lung Cancer2009;63:121-7

[23] Joerger M,Baas P,Smits PH.Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine..Cancer Chemother Pharmacol2012;69:25-33

[24] Herraez E,Macias RI,Bujanda L.Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib..Hepatology2013;58:1065-73

[25] Pongmaneratanakul S,Pengsuparp T.Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy..Asian Pac J Cancer Prev2017;18:857-61 PMCID:PMC5464510

[26] Xu X,Zhou B,Zhou H.Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients..Clin Exp Pharmacol Physiol2012;39:786-92

[27] Wlcek K,Riha J,Olszewski U.The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer..Cancer Biol Ther2011;11:801-11

[28] Hayer M,Bruss M.Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1)..Ann Hum Genet1999;63:473-82

[29] Makhtar SM,Baba AA.Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients..J Genet2018;97:835-42

[30] Cargnin S,Soverini S,Terrazzino S.Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis..Pharmacol Res2018;131:244-54

[31] Koren-Michowitz M,Ribakovsky E,Pessach I.OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients..Eur J Haematol2014;92:283-8

[32] Arimany-Nardi C,Lee-Verges E,Koepsell H.Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells..Pharmacogenomics J2015;15:363-71

[33] Geier A,Bettinger D,Bantel H.The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma..Oncotarget2017;8:15846-57 PMCID:PMC5362528

[34] Heise M,Knapstein J,Hoppe-Lotichius M.Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance..BMC Cancer2012;12:109 PMCID:PMC3323414

[35] Lautem A,Grasel A,Weiler N.Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma..Int J Oncol2013;42:1297-304

[36] Guttmann S,Groba SR,Sauer V.Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells..Oncotarget2018;9:743-54 PMCID:PMC5787505

[37] Gao PT,Gong ZJ,Sun YF.Low SLC29A1 expression is associated with poor prognosis in patients with hepatocellular carcinoma..Am J Cancer Res2017;7:2465-77 PMCID:PMC5752687

[38] Chen CF,Lin KT,Chang HW.Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma..Hepatology2010;52:1690-701

[39] Marin JJ,Briz O.Molecular bases of liver cancer refractoriness to pharmacological treatment..Curr Med Chem2010;17:709-40

[40] Huang WC,Hung CM,Chien YF,Tu CY,Hsu SC,Chen YJ.BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib..PLoS One2013;8:e83627 PMCID:PMC3877048

[41] Agarwal S,Ohlfest JR.The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain..J Pharmacol Exp Ther2011;336:223-33 PMCID:PMC3014301

[42] Lagas JS,Sparidans RW,Beijnen JH.Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation..Mol Cancer Ther2010;9:319-26

[43] Tandia M,Paule B,Cailliez V.Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study..Cancer Chemother Pharmacol2017;79:759-66

[44] Marin JJ,Perez MJ,Monte MJ.Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs..Front Biosci (Landmark Ed)2009;14:4257-80

[45] Ng IO,Fan ST.Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response..Am J Clin Pathol2000;113:355-63

[46] Kato A,Ambiru S,Ito H.Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection..J Surg Oncol2001;78:110-5

[47] Cao L,Windhovel U,Bruch HP.Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues..Eur J Cancer1998;34:1612-7

[48] Tepsiri N,Sripa B,Wongkham S.Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines..World J Gastroenterol2005;11:2748-53 PMCID:PMC4305909

[49] Wolf SJ,Wang J,Chong SS.An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics..Pharmacogenomics J2011;11:315-25

[50] Baldissera VD,Coral GP,Marroni CA.Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma..Ann Hepatol2012;11:899-906

[51] Kimchi-Sarfaty C,Kim IW,Calcagno AM,Gottesman MM.A "silent" polymorphism in the MDR1 gene changes substrate specificity..Science2007;315:525-8

[52] Su Z,Fang T,Zhang H.Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy..Am J Transl Res2016;8:2790-802 PMCID:PMC4931173

[53] Korita PV,Shirai Y,Sakata J.Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma..Oncol Rep2010;23:965-72

[54] Nies AT,Pfannschmidt M,Hofmann WJ.Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma..Int J Cancer2001;94:492-9

[55] Wakamatsu T,Hachimine D,Okazaki K.The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins..Int J Oncol2007;31:1465-72

[56] Martinez-Becerra P,Romero MR,Anadon C.No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors..Mol Pharm2012;9:1693-704

[57] Zhao J,Wang DY.Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma..World J Gastroenterol2010;16:6104-10 PMCID:PMC3012574

[58] Wang Z,Tang K,Chong SS.A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection..Hum Mol Genet2005;14:2075-87

[59] Wei D,Peng R,Bai R.ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib..Xenobiotica2017;47:1008-14

[60] Daly AK,Leathart JB,Dang TS.Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes..Gastroenterology2007;132:272-81

[61] Nguyen TD,Liu W,Baldwin RM.Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression..Pharmacogenomics J2013;13:396-402 PMCID:PMC3435480

[62] Lang T,Burk O,Keil A.Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver..Pharmacogenetics2004;14:155-64

[63] Edavana VK,Yao-Borengasser A,Dhakal IB.Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples..Int J Cancer Res Mol Mech2015;1: PMCID:PMC4790825

[64] Eclov RJ,Chhibber A,Ahituv N.ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression..Pharmacogenet Genomics2017;27:454-63 PMCID:PMC5678922

[65] Hoblinger A,Sauerbruch T.Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer..Digestion2009;80:36-9

[66] Li Z,Shan F,Xiao A.ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients..Oncotarget2016;7:55449-57 PMCID:PMC5342428

[67] Han ZG,Yu TT.Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population..Med Sci Monit2017;23:1999-2006 PMCID:PMC5414593

[68] Werk AN,Haenisch S.Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379..Pharmacogenet Genomics2014;24:283-91

[69] Shibayama Y,Maeda H,Ikeda R.Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib..Biol Pharm Bull2011;34:433-5

[70] Rau S,Riedel HD,Kulaksiz H.Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas..Eur J Clin Invest2008;38:134-42

[71] Tomonari T,Taniguchi T,Tanaka H.MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma..Oncotarget2016;7:7207-15 PMCID:PMC4872779

[72] Tsukamoto M,Satake K,Nakagawa H.Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4..Int J Mol Sci2017;18: PMCID:PMC5535926

[73] Lal S,Ooi LL,Wong NS.Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients..Pharmacogenomics J2017;17:337-43

[74] Krajinovic M,Drouin S,Rezgui A.Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia..Pharmacogenomics J2016;16:530-5

[75] Chen YL,Lin PY,Chu PY.ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients..Anticancer Res2016;36:2983-8

[76] Marin JJG,Briz O,Serrano MA.Molecular Bases of Chemoresistance in Cholangiocarcinoma..Curr Drug Targets2017;18:889-900

[77] Prasad B,Lin Y.Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype..J Pharm Sci2013;102:787-93

[78] Ahmed S,Zhou J.Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine..Genomics Proteomics Bioinformatics2016;14:298-313 PMCID:PMC5093856

[79] Zhou J,Li SF,Gao N.Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma..Oncotarget2016;7:50612-23 PMCID:PMC5226607

[80] Rochat B.Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism..Clin Pharmacokinet2005;44:349-66

[81] Zhong JH,Ma L,Li LQ.Meta-analysis of microsomal epoxide hydrolase gene polymorphism and risk of hepatocellular carcinoma..PLoS One2013;8:e57064 PMCID:PMC3581564

[82] Korobkova EA.Effect of natural polyphenols on CYP metabolism: implications for diseases..Chem Res Toxicol2015;28:1359-90

[83] Zanger UM.Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation..Pharmacol Ther2013;138:103-41

[84] Miyoshi Y,Kim SJ,Noguchi S.Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers..Breast Cancer2005;12:11-5

[85] Yan T,Xie C,Peng X.Severely impaired and dysregulated cytochrome p450 expression and activities in hepatocellular carcinoma: implications for personalized treatment in patients..Mol Cancer Ther2015;14:2874-86 PMCID:PMC4674380

[86] Fushiya N,Nishino H,Ohnishi A.Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma..Anticancer Drugs2013;24:617-22

[87] Sugiyama E,Kim SR,Hasegawa R.Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism..J Clin Oncol2007;25:32-42

[88] Fujimura T,Urano T,Murata T.Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer..Urology2009;74:391-7

[89] Oguro A,Suzuki S.Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth..Biol Pharm Bull2009;32:1962-7

[90] Omiecinski CJ,Hosagrahara V.Epoxide hydrolase--polymorphism and role in toxicology..Toxicol Lett2000;112-113:365-70

[91] Marin JJ,Monte MJ,Macias RI.Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs..Curr Cancer Drug Targets2012;12:402-38

[92] Hassett C,Sidhu JS.Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants..Hum Mol Genet1994;3:421-8 PMCID:PMC4868095

[93] Jiang W,He Y.Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy..Clin Cancer Res1997;3:395-9

[94] Walko CM.Will we ever be ready for blood level-guided therapy?.J Clin Oncol2008;26:2078-9

[95] Etienne-Grimaldi MC,Beroud C,van Kuilenburg A.New advances in DPYD genotype and risk of severe toxicity under capecitabine..PLoS One2017;12:e0175998 PMCID:PMC5421769

[96] Hiratsuka M,Akai F,Hishinuma E.Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity..PLoS One2015;10:e0124818 PMCID:PMC4411063

[97] Lin L,Tan Y,Kong F.Prognostic implication of NQO1 overexpression in hepatocellular carcinoma..Hum Pathol2017;69:31-7

[98] Buranrat B,Kukongviriyapan U,Kukongviriyapan V.Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells..World J Gastroenterol2010;16:2362-70 PMCID:PMC2874140

[99] Zhou JY,Yu HL,Ma WL.Association of NQO1 Pro187Ser polymorphism with the risks for colorectal cancer and colorectal adenoma: a meta-analysis..Int J Colorectal Dis2012;27:1123-4

[100] Kolesar JM,Marsh S,Johnson DH.The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer..Oncol Rep2011;25:1765-72 PMCID:PMC3211091

[101] Mameri H,Meseure D,Buhagiar-Labarchede G.Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer..Clin Cancer Res2017;23:2116-26

[102] Carpi FM,Ubaldi J,Polzonetti V.CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population..Pharmacogenomics2013;14:769-81

[103] Tibaldi C,Tiseo M,D'Incecco A.Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients..Ann Oncol2012;23:670-7

[104] Coulibaly ST,Winter F,Braye M.Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase..PLoS One2015;10:e0140741 PMCID:PMC4618062

[105] Akhdar H,Musso O,Joumaa W.The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals..PLoS One2016;11:e0167543 PMCID:PMC5147914

[106] Gamage N,Hempel N,Windmill KF.Human sulfotransferases and their role in chemical metabolism..Toxicol Sci2006;90:5-22

[107] Brandon EF,Meijerman I,Beijnen JH.In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug..Invest New Drugs2004;22:241-51

[108] Fernandez-Santander A,Novillo A,Rubio M.Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients..PLoS One2013;8:e70183 PMCID:PMC3726442

[109] Lu L,Shi J,Qi XX.Drug-metabolizing activity, protein and gene expression of udp-glucuronosyltransferases are significantly altered in hepatocellular carcinoma patients..PLoS One2015;10:e0127524 PMCID:PMC4444081

[110] Ye L,Guo E,Lu L.Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient..PLoS One2014;9:e96664 PMCID:PMC4010532

[111] Hu DG,Lu L,McKinnon RA.Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells..Drug Metab Dispos2015;43:660-8

[112] Zahreddine HA.Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells..Clin Cancer Res2015;21:2207-10 PMCID:PMC4433783

[113] Marin JJ,Martinez-Becerra P,Briz O.Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours..Curr Mol Med2009;9:1108-29

[114] Zheng YB,Zhao W,Huang JW.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib..Med Oncol2014;31:209

[115] Jain L,Danesi R,Dahut WL.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib..J Exp Clin Cancer Res2010;29:95 PMCID:PMC2913951

[116] Hansen TF,Andersen RF,Brandslund I.The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer..Pharmacogenomics J2011;11:53-60

[117] Orlandi P,Fioravanti A,Galli L.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide..Br J Cancer2013;109:957-64 PMCID:PMC3749570

[118] Scartozzi M,Svegliati Baroni G,Piscaglia F.VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study..Int J Cancer2014;135:1247-56

[119] Schulze K,Letouze E,Calderaro J.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets..Nat Genet2015;47:505-11 PMCID:PMC4587544

[120] Robertson S,Dodson R,Poling J.The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome..Hum Pathol2013;44:2768-73 PMCID:PMC3838441

[121] Angkathunyakul N,Heaton N,Quaglia A.BRAF V600E mutation in biliary proliferations associated with alpha1-antitrypsin deficiency..Histopathology2017;70:485-91

[122] Dow M,Tsui BY,Nakagawa H.Integrative genomic analysis of mouse and human hepatocellular carcinoma..Proc Natl Acad Sci U S A2018;115:E9879-E88 PMCID:PMC6196518

[123] Yamamoto M,Xin B,Yamazaki K.Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice..Mol Carcinog2017;56:478-88 PMCID:PMC5214095

[124] Crystal AS,Sequist LV,Niederst MJ.Patient-derived models of acquired resistance can identify effective drug combinations for cancer..Science2014;346:1480-6 PMCID:PMC4388482

[125] Bean J,Shih JY,Viale A.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib..Proc Natl Acad Sci U S A2007;104:20932-7 PMCID:PMC2409244

[126] Dong LQ,Ma LJ,Wang XY.Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma..J Hepatol2018;69:89-98

[127] Rad R,Rad L,Strong A.A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention..Cancer Cell2013;24:15-29 PMCID:PMC3706745

[128] Aboussekhra A,Shivji MK,Moncollin V.Mammalian DNA nucleotide excision repair reconstituted with purified protein components..Cell1995;80:859-68

[129] Zhou W,Liu G,Neuberg DS.Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy..Clin Cancer Res2004;10:4939-43

[130] Gurubhagavatula S,Park S,Su L.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy..J Clin Oncol2004;22:2594-601

[131] Yang Z.Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin..Int J Clin Exp Med2015;8:9931-6 PMCID:PMC4538105

[132] Golan T,Kelley RK,Borgida A.Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study..Oncologist2017;22:804-10 PMCID:PMC5507643

[133] Wardell CP,Yamada T,Fassan M.Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations..J Hepatol2018;68:959-69

[134] Zimmer AS,Lipkowitz S.Update on PARP Inhibitors in Breast Cancer..Curr Treat Options Oncol2018;19:21

[135] Ueda S,Morita K,Kayashima H.Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma..Ann Surg Oncol2011;18:1204-11

[136] Fautrel A,Musso O,Guillouzo A.Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma..J Hepatol2005;43:288-93

[137] Van Allen EM,Kim P,Wagle N.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma..Cancer Discov2014;4:1140-53 PMCID:PMC4238969

[138] Sishc BJ.The role of the core non-homologous end joining factors in carcinogenesis and cancer..Cancers (Basel)2017;9:E81 PMCID:PMC5532617

[139] Yang S.XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance..BMC Cancer2017;17:344 PMCID:PMC5437682

[140] Schulze K,Villanueva A.Genetic profiling of hepatocellular carcinoma using next-generation sequencing..J Hepatol2016;65:1031-42

[141] Bullock AN.Rescuing the function of mutant p53..Nat Rev Cancer2001;1:68-76

[142] Ye S,Hu XG,Xu QR.TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma..Oncol Rep2017;37:2215-26 PMCID:PMC5367355

[143] Woo HG,Budhu A,Kwon SM.Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma..Gastroenterology2011;140:1063-70 PMCID:PMC3057345

[144] Chan KT.Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line..Cancer Chemother Pharmacol2004;53:519-26

[145] Melino G.p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53..Cell Death Differ2011;18:1487-99 PMCID:PMC3178431

[146] Melino G,Ranalli M,Zong WX.p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation..J Biol Chem2004;279:8076-83

[147] Gonzalez R,Rufini A,Navarro-Villaran E.Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation..PLoS One2017;12:e0174326 PMCID:PMC5369777

[148] Mundt HM,Melino G,Schilling T.Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways..Biochem Biophys Res Commun2010;396:335-41

[149] Kayhanian H,Braconi C.Emerging molecular targets and therapy for cholangiocarcinoma..World J Gastrointest Oncol2017;9:268-80 PMCID:PMC5534395

[150] Nutthasirikul N,Leelayuwat C,Jearanaikoon P.Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma..Int J Oncol2013;42:1181-8

[151] Nutthasirikul N,Techasen A,Leelayuwat C.Targeting the 133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells..Int J Oncol2015;47:2153-64

[152] Ahn DH,Ahn CW,Mikhail S.Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance..Cancer2016;122:3657-66 PMCID:PMC5222890

[153] Namwat N,Loilome W,Sripa B.Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines..Chemotherapy2008;54:343-51

[154] Soung YH,Kim SY,Park WS.Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas..Oncogene2005;24:141-7

[155] Ahn SM,Shim JH,Hong SM.Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification..Hepatology2014;60:1972-82

[156] Wattanawongdon W,Namwat N,Boonmars T.Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness..Int J Oncol2015;47:398-410

[157] Wang Z,Gao XM,Wang XY.Beta-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma..Mol Clin Oncol2015;3:936-40 PMCID:PMC4487080

[158] Hsu HC,Mao TL,Lai PL.Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis..Am J Pathol2000;157:763-70 PMCID:PMC1885685

[159] Nhieu JT,Wei Y,Zafrani ES.Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation..Am J Pathol1999;155:703-10 PMCID:PMC1866892

[160] Inagawa S,Adachi S,Hori M.Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival..Clin Cancer Res2002;8:450-6

[161] Kan Z,Liu X,Barber TD.Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma..Genome Res2013;23:1422-33 PMCID:PMC3759719

[162] Yokoyama M,Ohtsuka K,Ohkura Y.KRAS mutation as a potential prognostic biomarker of biliary tract cancers..Jpn Clin Med2016;7:33-9 PMCID:PMC5156551

[163] Yeung Y,Chionh F,Tse JWT.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines..Mol Oncol2017;11:1130-42 PMCID:PMC5579335

[164] Yu C,Huang L,Chen L.Deciphering the spectrum of mitochondrial DNA mutations in hepatocellular carcinoma using high-throughput sequencing..Gene Expr2018;18:125-34 PMCID:PMC5954625

[165] Kawamura N,Bando K,Matsumoto S.PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors..Jpn J Cancer Res1999;90:413-8 PMCID:PMC5926086

[166] Fujiwara Y,Yamada T,Gotoh M.PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas..Jpn J Cancer Res2000;91:287-92 PMCID:PMC5926370

[167] Ho DWH,Chiu YT,Poon RTP.TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication..Gut2017;66:1496-506 PMCID:PMC5530480

[168] Galmarini CM,Audoynaud C,Falette N.A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells..Int J Cancer2006;119:60-6

[169] Fulda S.Tumor resistance to apoptosis..Int J Cancer2009;124:511-5

[170] Li M,Gao J,Zhang CL.Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute myeloid leukemia by impairing procaspase-8 dimerization..Cell Death Dis2018;9:516 PMCID:PMC5938697

[171] Zhou L,Li J.The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma..Med Oncol2010;27:255-61

[172] Tanaka Y,Tada M,Guleng B.Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients..Oncogene2006;25:2950-2

[173] Lee JW,Kim SY,Park WS.PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas..Oncogene2005;24:1477-80

[174] Kudo Y,Tateishi K,Yamamoto S.Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway..J Hepatol2011;55:1400-8

[175] Dogruluk T,Espitia M,Chen T.Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations..Cancer Res2015;75:5341-54 PMCID:PMC4681596

[176] Chen KF,Tai WT,Hsu CH.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells..J Pharmacol Exp Ther2011;337:155-61

[177] Wang L,Zhang Y,Zhang J.Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma..Hepatol Res2007;37:389-96

[178] Zhou Q,Yeo W.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma..Future Oncol2011;7:1149-67

[179] Huynh H,Chan SL,Ong R.Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus..Mol Cancer Ther2015;14:1224-35

[180] Tai WT,Shiau CW,Ko CH.Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3..Mol Cancer Ther2012;11:452-63

[181] Yang S,Gu Q,Wang G.Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma..Oncotarget2016;7:5461-9 PMCID:PMC4868698

[182] Rao CV,Yamada HY.Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer..Carcinogenesis2017;38:2-11 PMCID:PMC5219050

[183] Ou DL,Chang YC,Liou JY.Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway..PLoS One2013;8:e66589 PMCID:PMC3688529

[184] Tovar V,Moeini A,Hoshida Y.Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma..Gut2017;66:530-40 PMCID:PMC5600200

[185] Lee YI,Lee SY,Park YJ.Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249..Mol Cell Endocrinol2003;203:51-63

[186] Huang WC,Chan CC.Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma..J Formos Med Assoc2017;116:464-8

[187] Xu RF,Zhang SR,Li LB.KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients..Biomed Pharmacother2011;65:22-6

[188] Scheffzek K,Kabsch W,Lautwein A.The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants..Science1997;277:333-8

[189] Rashid A,Gao YT,Wallace C.K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China..Clin Cancer Res2002;8:3156-63

[190] Yin PH,Lin JC,Wei YH.Somatic mutations of mitochondrial genome in hepatocellular carcinoma..Mitochondrion2010;10:174-82

[191] Levine B.Autophagy in the pathogenesis of disease..Cell2008;132:27-42 PMCID:PMC2696814

[192] Sui X,Wang Z,Kong N.Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment..Cell Death Dis2013;4:e838 PMCID:PMC3824660

[193] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[194] Leyva-Illades D,Quinn M.Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment..Transl Gastrointest Cancer2012;1:71-80 PMCID:PMC3448449

[195] Yamada S,Wei L,Fujii T.Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma..Ann Surg Oncol2014;21:3882-90

[196] Giannelli G,Dituri F.Role of epithelial to mesenchymal transition in hepatocellular carcinoma..J Hepatol2016;65:798-808

[197] Kong P,Saxena A,Frangogiannis NG.Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis..Am J Physiol Heart Circ Physiol2013;305:H1363-72 PMCID:PMC3840245

[198] Kremmer E,Kummer U,Mysliwietz J.Neutralization of immunosuppression by antibodies against variable as well as constant regions of monoclonal anti-Thy-1 xenoantibodies and their ability to be suppressed by initial T cell depletion..Transplantation1989;47:641-6

[199] Vaquero J,Claperon A,Paradis V.Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks..J Hepatol2017;66:424-41

[200] Araki K,Suzuki H,Wada W.E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma..Br J Cancer2011;105:1885-93 PMCID:PMC3251878

[201] Sheng L,Xu H.Effect of slug-mediated down-regulation of e-cadherin on invasiveness and metastasis of anaplastic thyroid cancer cells..Med Sci Monit2017;23:138-43 PMCID:PMC5242203

[202] Endo K,Miyake N.E-cadherin gene mutations in human intrahepatic cholangiocarcinoma..J Pathol2001;193:310-7

[203] Lee S,Jung HY,Kang GH.Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma..Am J Pathol2002;161:1015-22 PMCID:PMC1867260

[204] Yang B,Guo M,Clark DP.Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma..Mod Pathol2005;18:412-20

[205] Yamada D,Wada H,Marubashi S.Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer..Eur J Cancer2013;49:1725-40

[206] Zhang Y,Ma J,Qu Y.Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance..J Exp Clin Cancer Res2016;35:111 PMCID:PMC4944516

[207] Warzecha CC,Amirikian K,Lu H.An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition..EMBO J2010;29:3286-300 PMCID:PMC2957203

[208] Brown RL,Damerow MS,Chodosh LA.CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression..J Clin Invest2011;121:1064-74 PMCID:PMC3049398

[209] Shapiro IM,Flytzanis NC,Condeelis JS.An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype..PLoS Genet2011;7:e1002218 PMCID:PMC3158048